Efficacy of tirofiban in treatment of acute cerebral infarction beyond the time window and with the type of anterior circulation artery atherosclerosis
Objective To evaluate the efficacy of tirofiban injection in treatment of acute cerebral infarction beyond the time window and with the type of anterior circulation artery atherosclerosis.Methods A total of 66 patients with acute cerebral infarction with the type of anterior circulation artery atherosclerosis admitted to the Department of Neurology of Wenzhou Central Hospital from November 2021 to December 2022 were selected as study objects,and they were divided into treatment group and control group by random number table method,with 33 cases in each group.The control group was given aspirin enteric-coated tablets.The treatment group was given intravenous infusion of tirofiban injection for 48 hours,bridging conventional antiplatelet therapy.The course of treatment was 2 weeks and the follow-up was 6 months.Before and after treatment,National Institutes of Health stroke scale(NIHSS)score,modified Rankin scale(MRS)score,modified Barthel index(MBI)score,thromboelasmogram and cerebral infarction hemorrhage transformation of two groups were compared.Results After 14 days of treatment,the NIHSS score in treatment group was significantly lower than before treatment(P<0.01),and significantly lower than that in control group(P<0.05).After 14 days of treatment and 6 months of follow-up,MRS scores in both groups were significantly lower than before treatment(P<0.01).After 6 months of follow-up,MRS scores in treatment group were significantly lower than those in control group(P<0.05).After 7 and 14 days of treatment and 6 months of follow-up,the MBI scores of patients in treatment group were significantly higher than before treatment(P<0.05).After 14 days of treatment and 6 months of follow-up,MBI scores in treatment group were significantly higher than those in control group(P<0.05).After treatment,the platelet aggregation inhibition rate in treatment group was significantly higher than that in control group(P<0.01),and the platelet activity was significantly lower than that in control group(P<0.01).No cerebral infarction hemorrhage transformation occurred in both groups.Conclusion Tirofiban bridging conventional antiplatelet therapy can prevent the neurological deterioration of acute cerebral infarction,greatly reduce the rate of disability,improve patients'life ability,and do not increase the risk of cerebral hemorrhage.
国家科技期刊平台
NSTL
万方数据
